Pfizer agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. The company also reported positive topline Phase 3 results for LITFULO in adults and adolescents with nonsegmental vitiligo, highlighting progress in its immunology pipeline. The settlement is relatively small compared to Pfizer's multi-billion-dollar revenue and helps clear a product-specific legal overhang. The LITFULO data supports Pfizer's strategy to expand in immunology and specialty therapies as it seeks to diversify beyond older products and upcoming patent expiries. Investors will be watching for global regulatory submissions for LITFULO in vitiligo and clearer disclosure on how dermatology and immunology launches contribute to the company's revised 2026 revenue guidance of US$60.5 billion to US$62.5 billion.
Pfizer IncSettlement clears legal overhang; positive Phase 3 results for LITFULO support pipeline.
